USL311: Phase I/II started

Upsher-Smith began an open-label, dose-escalation, international Phase I/II trial to evaluate once-weekly

Read the full 120 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE